WHO-EORTC classification for cutaneous lymphomas.
By R. Willemze, Elaine S. Jaffe, G. Burg, L. Cerroni, E. Berti, S. Swerdlow, E. Ralfkiaer, S. Chimenti, J. Díaz-Pérez, L. Duncan and 14 more. Blood, 2005
3,899 citations recorded by the source corpus.
Subfields: Dermatology, Neurology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/49a1790a72ec21a1bf8c44a1d82d209f55e5411f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pathology and Forensic Medicine
Citations in the corpus
- The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. (2011, background): “In addition, the WHO/EORTC consensus classification of cutaneous lymphomas was largely adopted.(8;9) The issue of grading of follicular lymphoma was revisited.”
- Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. (2007, background): “Cutaneous T-cell lymphomas (CTCLs) are a group of non-Hodgkin’s lymphomas that initially present in the skin and may ultimately involve lymph nodes, blood, and visceral organs.(1,2) The majority of instances of CTCL are classified as mycosis fungoides (MF) or Sézary syndrome (SS), both characterized”
- The 2008 WHO classification of lymphomas: implications for clinical practice and translational research (2009, neutral): “Other site-specific categories are primary DLBCL of the central nervous system (CNS),(50) and primary cutaneous DLBCL, leg-type.(51) Interestingly, the “leg-type” of primary cutaneous DLBCL exhibits an activated B-cell (ABC) gene expression profile in most cases.”
- Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. (2010, background): “MF is indolent, SS is generally associated with a poor prognosis.(2) Long-term follow-up studies of MF/SS are limited,(3-8) with the largest study consisting of 525 patients(8) and only two studies reporting actuarial survival data.”
- Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). (2007, background): “In addition, it has become clear that the non-MF/non-SS subtypes of CTCL neither share the same T or N stages nor have the same prognosis as MF and SS.(6,7) The purpose of revising the MFCG staging and classification system now is to incorporate these advances and new data; to exclude the non-MF/non”